ADAM metallopeptidase with thrombospondin type 1 motif 9Genealiases: []
Q-omics provides the consensus-scored ADAMTS9 profile across patient tissues and cancer cell-line models. ADAMTS9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADAMTS9 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ADAMTS9 RNA expression shows 19,088 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KICH, and KIRP as cancer lineages where ADAMTS9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS9 survival associations across molecular data types. ADAMTS9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (14) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS9 RNA expression–survival associations across cancer types. High ADAMTS9 expression shows unfavorable associations in UVM, ACC, BLCA, LGG and LIHC, but favorable associations in THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADAMTS9 RNA expression.
This table summarizes ADAMTS9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ADAMTS9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS9 shows lower tumor expression in KICH and BRCA and higher tumor expression in THCA, LIHC, KIRP and COAD. The KICH box plot shows higher ADAMTS9 RNA expression in normal versus tumor tissue (log2 FC = −2.187, t-test p < 0.001).
This table shows molecular features associated with ADAMTS9 in patient tissues and cancer cell lines. In patient samples, ADAMTS9 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
